The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2026 | HERIZON-GEA-01: zanidatamab + chemotherapy +/- tislelizumab improves PFS in 2L HER2+ mGEA
Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses findings from the HERIZON-GEA-01 trial (NCT05152147) which evaluated zanidatamab with chemotherapy ± tislelizumab for first-line (1L) HER2-positive (HER2+) locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma. Both zanidatamab-based regimens demonstrated clincially meaningful and stastistically significant increases in progression-free survival. This interview took place at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
